insulin glp-1 Receptor Agonists JCI Insight - GLP-1 receptor

It is important to understand that retatrutide is not currently approved for use in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)

The cohort was predominantly female (78.6%) with a mean age of 52.7 years

Another scenario is a patient who has been using a GLP-1 therapy for a few years, has reached a weight-loss plateau, and is now in the maintenance phase of treatment

Tirzepatide SC (Mounjaro/Zepbound): Dual GIP/GLP-1 agonism produces the greatest weight reduction among approved agents up to 2024% in non-diabetic patients (SURMOUNT-1)